Trials / Sponsors / Immatics US, Inc.
Immatics US, Inc.
Industry · 7 registered clinical trials — 3 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | ACTengine® IMA203 Combined With mRNA-4203 Cutaneous Melanoma, Synovial Sarcoma | Phase 1 | 2025-07-25 |
| Recruiting | SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metast Melanoma, Cutaneous Malignant | Phase 3 | 2025-01-14 |
| Recruiting | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Sol Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult | Phase 1 / Phase 2 | 2019-05-14 |
| Completed | TCR-engineered T Cells in Solid Tumors: IMA202-101 Solid Tumor, Adult, Refractory Cancer, Recurrent Cancer | Phase 1 | 2019-05-02 |
| Completed | Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling Refractory Cancer, Recurrent Cancer, Adult Solid Tumor | — | 2019-02-26 |
| Completed | TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) Solid Tumor, Cancer, Recurrent Solid Tumors | Phase 1 | 2018-12-19 |
| Completed | ACTolog in Patients With Solid Cancers Cancer, Solid Tumor | Phase 1 | 2017-06-30 |